Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
| ▸ | EIF4E | P06730 | 3/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.35 |
| ▸ | UMPS | P11172 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TK1 | P04183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146413 | 0.93 | P2RY2 (0.45) | PNPP2RY2P2RY4POLB | |
| SCHEMBL3141537 | 0.91 | P2RY2 (0.47) | P2RY2P2RY4POLB | |
| SCHEMBL3133822 | 0.83 | PNP (0.42) | EIF4EPNPP2RY2P2RY4 | |
| SCHEMBL264671 | 0.76 | HPRT1 (0.41) | HPRT1EIF4EP2RY2P2RY4UMPS | |
| SCHEMBL12261233 | 0.76 | HPRT1 (0.41) | HPRT1EIF4EP2RY2P2RY4UMPS | |
| SCHEMBL6906442 | 0.71 | P2RY2 (0.48) | P2RY2P2RY4 | |
| SCHEMBL10819909 | 0.70 | NT5E (0.57) | P2RY2P2RY4TAS1R3TAS1R1NT5E | |
| SCHEMBL1577230 | 0.70 | NT5E (0.57) | P2RY2P2RY4TAS1R3TAS1R1NT5E | |
| SCHEMBL15468735 | 0.70 | NT5E (0.57) | P2RY2P2RY4TAS1R3TAS1R1NT5E | |
| SCHEMBL12477759 | 0.70 | P2RY2 (0.45) | EIF4EPNPP2RY2P2RY4TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307434-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2476690-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GOT1 | HPRT1 103/4885EIF4E 1683/4885PNP 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.